ASTRO 2022 | Using DCISionRT to assess benefit of radiotherapy in patients with DCIS following lumpectomy

Chirag Shah, MD, Cleveland Clinic, Cleveland, OH, discusses the results of a study investigating the benefit of radiation therapy following lumpectomy in patients of varying clinical risk levels with ductal carcinoma in situ (DCIS). Patient clinical risk level was determined using a novel biosignature, DCISionRT. This method of categorisation was found to identify clinical risk level more effectively than traditional clinicopathological features. The study found that 37% of the low-risk DCIS patient cohort received no significant benefit of radiation therapy following lumpectomy. Elevated-risk DCIS patients received a significant benefit, with a 15% reduction in recurrence in the breast after radiation therapy following lumpectomy. Finally, residual-risk patients received a significant benefit of radiation therapy following lumpectomy, however risk of recurrence remained elevated by 15%. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.